Market Closed -
OTC Markets
03:57:02 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.0001
USD
|
0.00%
|
|
0.00%
|
+9,900.00%
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Capitalization
1 |
128.2
|
121.5
|
52.64
|
5.52
|
12.99
|
8.547
|
Enterprise Value (EV)
1 |
128.1
|
123.9
|
53.18
|
8.537
|
14.18
|
12.23
|
P/E ratio
|
-19.3
x
|
-3.39
x
|
-4.16
x
|
-0.17
x
|
-0.33
x
|
-0.62
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
14,686
x
|
4,529
x
|
209
x
|
7.94
x
|
46.3
x
|
8.3
x
|
EV / Revenue
|
14,670
x
|
4,617
x
|
211
x
|
12.3
x
|
50.5
x
|
11.9
x
|
EV / EBITDA
|
-27
x
|
-5.83
x
|
-14
x
|
-1.32
x
|
-2.92
x
|
-2.65
x
|
EV / FCF
|
-
|
7,430,302
x
|
-5,653,707
x
|
1,912,111
x
|
-5,212,949
x
|
-1,745,074
x
|
FCF Yield
|
-
|
0%
|
-0%
|
0%
|
-0%
|
-0%
|
Price to Book
|
-939
x
|
-12
x
|
-16.5
x
|
-0.53
x
|
-2.37
x
|
40
x
|
Nbr of stocks (in thousands)
|
26,377
|
34,439
|
43,222
|
76,143
|
3,136,775
|
7,122,806
|
Reference price
2 |
4.860
|
3.528
|
1.218
|
0.0725
|
0.004140
|
0.001200
|
Announcement Date
|
5/23/17
|
4/17/18
|
4/15/19
|
5/14/20
|
4/14/21
|
4/15/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net sales
1 |
0.008729
|
0.0268
|
0.2521
|
0.6951
|
0.2807
|
1.03
|
EBITDA
1 |
-4.736
|
-21.26
|
-3.81
|
-6.464
|
-4.849
|
-4.61
|
EBIT
1 |
-4.738
|
-21.26
|
-3.815
|
-6.471
|
-4.855
|
-4.711
|
Operating Margin
|
-54,284.2%
|
-79,250.09%
|
-1,513.06%
|
-930.95%
|
-1,729.86%
|
-457.28%
|
Earnings before Tax (EBT)
1 |
-5.402
|
-33.44
|
-11.1
|
-20.18
|
-12.15
|
-10.19
|
Net income
1 |
-5.402
|
-33.44
|
-11.1
|
-20.18
|
-12.15
|
-10.19
|
Net margin
|
-61,890.89%
|
-124,643.76%
|
-4,400.73%
|
-2,903.33%
|
-4,327.54%
|
-989.22%
|
EPS
2 |
-0.2520
|
-1.040
|
-0.2926
|
-0.4146
|
-0.0126
|
-0.001941
|
Free Cash Flow
|
-
|
16.67
|
-9.407
|
4.465
|
-2.721
|
-7.01
|
FCF margin
|
-
|
62,131.31%
|
-3,730.96%
|
642.33%
|
-969.42%
|
-680.41%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/23/17
|
4/17/18
|
4/15/19
|
5/14/20
|
4/14/21
|
4/15/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net Debt
1 |
-
|
2.36
|
0.54
|
3.02
|
1.2
|
3.69
|
Net Cash position
1 |
0.14
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.111
x
|
-0.1417
x
|
-0.4667
x
|
-0.2468
x
|
-0.7995
x
|
Free Cash Flow
|
-
|
16.7
|
-9.41
|
4.46
|
-2.72
|
-7.01
|
ROE (net income / shareholders' equity)
|
2,112%
|
640%
|
165%
|
294%
|
151%
|
390%
|
ROA (Net income/ Total Assets)
|
-
|
-1,940%
|
-156%
|
-264%
|
-187%
|
-58.5%
|
Assets
1 |
-
|
1.724
|
7.096
|
7.643
|
6.505
|
17.42
|
Book Value Per Share
2 |
-0.0100
|
-0.2900
|
-0.0700
|
-0.1400
|
-0
|
0
|
Cash Flow per Share
2 |
0.0100
|
0.0100
|
0.0100
|
0
|
0
|
0
|
Capex
|
-
|
0.02
|
0
|
0
|
0.01
|
0.13
|
Capex / Sales
|
-
|
60.17%
|
1.67%
|
0.34%
|
2.14%
|
12.26%
|
Announcement Date
|
5/23/17
|
4/17/18
|
4/15/19
|
5/14/20
|
4/14/21
|
4/15/22
|
|
1st Jan change
|
Capi.
|
---|
| +9,900.00% | 2.21M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|